S U N DAY, J U LY 2 5 , 2 0 2 1 | A S C R S A N N UA L M E E T I N G
DAILY NEWS
T
he 2021 ASCRS Annual
Meeting kicked off on
Saturday morning with the
Opening General Session.
Edward Holland, MD, chair of the
ASCRS Program Committee, be-
gan by addressing attendees. "We
are so delighted to be back in the
most effective learning environ-
ment together in person," he said.
There is some outstanding clinical
education, Dr. Holland said, add-
ing that the Exhibit Hall features
more than 200 companies.
Dr. Hoffman discusses goals for his term as
ASCRS president.
Source: ASCRS
T
his year's Binkhorst
Lecture was delivered by
Richard Lewis, MD, on the
topic of "We Can Prevent
Blindness in Glaucoma – Why
Don't We?"
He started by discussing the
history of glaucoma, looking at
the first 2,000 years of the dis-
ease. Very little was done to help
with the diagnosis and treatment
in those years, he said. Then he
moved on to discuss glaucoma
in the 20th century, mentioning
the enlightened understanding
of how the disease causes blind-
ness; defining glaucoma and its
many causes; safer, more effective
medications to lower IOP; and use
of trabs and tubes reserved for
advanced disease and after medi-
cation failure.
Between 1965–1980, Dr.
Lewis said the probability of
blindness from open angle glau-
coma was 25.8%, and between
1981–2000, the probability was
13.1%. In the last 20 years, there
have been more accurate diagnos-
tics, therapies with greater IOP
lowering, and less complicated
surgeries. He also highlighted a
number of landmark glaucoma
studies.
continued on page 4
continued on page 3
OT
1
BVI
1
Binkhorst Lecture addresses blindness in glaucoma
ASCRS Annual Meeting officially kicks off
with Opening General Session
Visit Booth 5208 to Hear
What's New at BVI
BVI and all other trademarks (unless noted otherwise) are property of BVI. BVI ©2021
FOR MORE INFORMATION,
VISIT US AT BOOTH #5201
SO YOUR PATIENTS
DON'T HAVE TO
© 2021 Ocular Therapeutix, Inc. All rights reserved. DEXTENZA is a registered trademark of Ocular Therapeutix, Inc. PP-US-DX-0323